Kura Oncology (KURA) Stock Forecast & Price Target

$10.20 +0.23 (+2.27%)

As of 03:19 PM Eastern

Compare

Kura Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
2

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Kura Oncology in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 2 have given a hold rating, and 10 have given a buy rating for KURA.

Consensus Price Target

$25.90
154.02% Upside

According to the 13 analysts' twelve-month price targets for Kura Oncology, the average price target is $25.90. The highest price target for KURA is $40.00, while the lowest price target for KURA is $15.00. The average price target represents a forecasted upside of 154.02% from the current price of $10.20.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for KURA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kura Oncology and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KURA Analyst Ratings Over Time

Type	Current Forecast 5/29/25 to 5/29/26	1 Month Ago 4/29/25 to 4/29/26	3 Months Ago 2/28/25 to 2/28/26	1 Year Ago 5/29/24 to 5/29/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.90	$26.38	$28.00	$24.50
Forecasted Upside	154.02% Upside	201.43% Upside	220.73% Upside	320.96% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

KURA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KURA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kura Oncology Stock vs. The Competition

Type	Kura Oncology	Medical Companies	Broader Market
Consensus Rating Score	2.69	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	159.78% Upside	1,706.94% Upside	14.47% Upside
News Sentiment Rating	Negative News See Recent KURA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/28/2026	Oppenheimer 3 of 5 stars		Set Target		$24.00	+134.37%
5/28/2026	Jefferies Financial Group 2 of 5 stars		Set Target		$24.00	+134.37%
5/28/2026	Citigroup 4 of 5 stars		Reiterated Rating	Market Outperform
4/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
4/14/2026	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Brims Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$23.00	+163.76%
3/24/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mara Goldstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$30.00 ➝ $25.00	+211.91%
3/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Dai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$16.00 ➝ $15.00	+74.28%
3/6/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Driscoll Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$38.00 ➝ $36.00	+323.03%
2/26/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
1/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Outperform	$25.00 ➝ $20.00	+121.36%
Get the Latest News and Ratings for KURA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.
1/13/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$40.00	+336.20%
11/24/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00 ➝ $28.00	+150.67%
10/20/2025	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reni J. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00	+144.32%
9/4/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brad Canino Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral
6/26/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Li Watsek Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
2/6/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Zelin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/8/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Sector Perform	$18.00 ➝ $10.00	+22.40%
11/22/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$36.00 ➝ $29.00	+189.97%
11/21/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
10/22/2024	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
10/14/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$26.00 ➝ $19.00	+2.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:12 PM ET.

KURA Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Kura Oncology is $25.90, with a high forecast of $40.00 and a low forecast of $15.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There is currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares.

According to analysts, Kura Oncology's stock has a predicted upside of 154.02% based on their 12-month stock forecasts.

Kura Oncology has been rated by research analysts at Citigroup, Jefferies Financial Group, Lake Street Capital, Mizuho, Oppenheimer, UBS Group, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Kura Oncology more than other "medical" companies. The consensus rating for Kura Oncology is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how KURA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Kura Oncology Recommendations

This page (NASDAQ:KURA) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

KURA Analyst Ratings Over Time

KURA Analyst Recommendations By Month

KURA Price Targets by Month

Kura Oncology Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

KURA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Kura Oncology Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

KURA Analyst Ratings Over Time

KURA Analyst Recommendations By Month

KURA Price Targets by Month

Kura Oncology Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

KURA Forecast - Frequently Asked Questions

What is Kura Oncology's forecast for 2026?

Should I buy or sell Kura Oncology stock right now?

Does Kura Oncology's stock price have much upside?

What analysts cover Kura Oncology?

Do Wall Street analysts like Kura Oncology more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Kura Oncology Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools